Simulating realistic patient profiles from pharmacokinetic models by a machine learning postprocessing correction of residual variability

IF 3.1 3区 医学 Q2 PHARMACOLOGY & PHARMACY CPT: Pharmacometrics & Systems Pharmacology Pub Date : 2024-06-14 DOI:10.1002/psp4.13182
Christos Kaikousidis, Robert R. Bies, Aristides Dokoumetzidis
{"title":"Simulating realistic patient profiles from pharmacokinetic models by a machine learning postprocessing correction of residual variability","authors":"Christos Kaikousidis,&nbsp;Robert R. Bies,&nbsp;Aristides Dokoumetzidis","doi":"10.1002/psp4.13182","DOIUrl":null,"url":null,"abstract":"<p>We address the problem of model misspecification in population pharmacokinetics (PopPK), by modeling residual unexplained variability (RUV) by machine learning (ML) methods in a postprocessing step after conventional model building. The practical purpose of the method is the generation of realistic virtual patient profiles and the quantification of the extent of model misspecification, by introducing an appropriate metric, to be used as an additional diagnostic of model quality. The proposed methodology consists of the following steps: After developing a PopPK model, the individual residual errors <i>IRES = DV–IPRED</i>, are computed, where DV are the observations and IPRED the individual predictions and are modeled by ML to obtain <i>IRES</i><sub><i>ML</i></sub>. Correction of the IPREDs can then be carried out as <i>DV</i><sub><i>ML</i></sub> <i>= IPRED + IRES</i><sub><i>ML</i></sub>. The methodology was tested in a PK study of ropinirole, for which a PopPK model was developed while a second deliberately misspecified model was also considered. Various supervised ML algorithms were tested, among which Random Forest gave the best results. The ML model was able to correct individual predictions as inspected in diagnostic plots and most importantly it simulated realistic profiles that resembled the real data and canceled out the artifacts introduced by the elevated RUV, even in the case of the heavily misspecified model. Furthermore, a metric to quantify the extent of model misspecification was introduced based on the <i>R</i><sup>2</sup> between IRES and IRES<sub>ML</sub>, following the rationale that the greater the extent of variability explained by the ML model, the higher the degree of model misspecification present in the original model.</p>","PeriodicalId":10774,"journal":{"name":"CPT: Pharmacometrics & Systems Pharmacology","volume":null,"pages":null},"PeriodicalIF":3.1000,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/psp4.13182","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CPT: Pharmacometrics & Systems Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/psp4.13182","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

We address the problem of model misspecification in population pharmacokinetics (PopPK), by modeling residual unexplained variability (RUV) by machine learning (ML) methods in a postprocessing step after conventional model building. The practical purpose of the method is the generation of realistic virtual patient profiles and the quantification of the extent of model misspecification, by introducing an appropriate metric, to be used as an additional diagnostic of model quality. The proposed methodology consists of the following steps: After developing a PopPK model, the individual residual errors IRES = DV–IPRED, are computed, where DV are the observations and IPRED the individual predictions and are modeled by ML to obtain IRESML. Correction of the IPREDs can then be carried out as DVML= IPRED + IRESML. The methodology was tested in a PK study of ropinirole, for which a PopPK model was developed while a second deliberately misspecified model was also considered. Various supervised ML algorithms were tested, among which Random Forest gave the best results. The ML model was able to correct individual predictions as inspected in diagnostic plots and most importantly it simulated realistic profiles that resembled the real data and canceled out the artifacts introduced by the elevated RUV, even in the case of the heavily misspecified model. Furthermore, a metric to quantify the extent of model misspecification was introduced based on the R2 between IRES and IRESML, following the rationale that the greater the extent of variability explained by the ML model, the higher the degree of model misspecification present in the original model.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
通过对残余变异性进行机器学习后处理修正,从药物动力学模型模拟真实的患者特征。
我们在传统模型建立后的后处理步骤中,通过机器学习(ML)方法对残余未解释变异性(RUV)进行建模,从而解决群体药代动力学(PopPK)中的模型失范问题。该方法的实际目的是生成逼真的虚拟患者档案,并通过引入适当的指标量化模型的失当程度,作为模型质量的额外诊断依据。建议的方法包括以下步骤:在建立 PopPK 模型后,计算个体残差误差 IRES = DV-IPRED,其中 DV 为观测值,IPRED 为个体预测值,通过 ML 建模得到 IRESML。IPRED 的校正可按 DVML = IPRED + IRESML 进行。该方法在罗匹尼罗(ropinirole)的 PK 研究中进行了测试,为此开发了一个 PopPK 模型,同时还考虑了第二个故意错误定义的模型。对各种有监督的 ML 算法进行了测试,其中随机森林算法的结果最好。ML 模型能够纠正诊断图中的个别预测,最重要的是,它模拟出了与真实数据相似的逼真剖面,并消除了 RUV 升高所带来的假象,即使是在严重误定模型的情况下也是如此。此外,还根据 IRES 和 IRESML 之间的 R2,引入了一个量化模型错配程度的指标,其原理是 ML 模型解释的变异程度越大,原始模型中存在的模型错配程度就越高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.00
自引率
11.40%
发文量
146
审稿时长
8 weeks
期刊最新文献
A model-informed clinical trial simulation tool with a graphical user interface for Duchenne muscular dystrophy. Physiology-based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab. Interim analysis, a tool to enhance efficiency of pharmacokinetic studies: Pharmacokinetics of rifampicin in lactating mother-infant pairs. PBPK modeling: What is the role of CYP3A4 expression in the gastrointestinal tract to accurately predict first-pass metabolism? Immunostimulatory/Immunodynamic model of mRNA-1273 to guide pediatric vaccine dose selection.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1